[5] [10] Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose
By contrast, with compounded or gray-market peptide products, it's much harder to know if the molecule is exactly what it claims to be, if the dose is correct, whether the vial is sterile, or whether there are contaminants like heavy metals or bacteria present or if it's even a different drug altogether
Therefore, it is not a question of whether tirzepatide can activate the mGIPR, but rather what doses of tirzepatide are required to do so
COA and SDS for released lots, within the analytical scope described on this page
Finally, we performed a sentiment analysis on all discussions using a separate, pretrained language model was used to classify sentiment (i.e., positive, neutral, or negative)